Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The website footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-11-03T16:00:23.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    A notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears on the page, and the site revision number changes from v3.7.1 to v3.7.2.
    Difference
    0.7%
    Check dated 2026-10-20T17:18:05.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision number advances from v3.7.0 to v3.7.1; the study record content remains unchanged.
    Difference
    0.1%
    Check dated 2026-10-06T18:54:01.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The record history now shows a new revision v3.7.0 added and the previous revision v3.6.6 removed, reflecting an updated version of the study record.
    Difference
    0.1%
    Check dated 2026-09-15T20:30:46.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The revision tag in the study history updated from v3.6.5 to v3.6.6. This indicates a new internal revision entry has been posted to the record.
    Difference
    0.1%
    Check dated 2026-09-01T18:01:13.000Z thumbnail image
  7. Check
    89 days ago
    Change Detected
    Summary
    A new revision entry labeled v3.6.5 has been added to the study record history. The previous revision entry v3.6.4 has been removed.
    Difference
    0.1%
    Check dated 2026-08-11T08:09:12.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.